Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. Transparent Traders Message Board

$ENDP $190M deal: Endo buying North Jersey special

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 4527
(Total Views: 591)
Posted On: 04/26/2018 11:05:42 AM
Avatar
Posted By: jonny_red32
$ENDP $190M deal: Endo buying North Jersey specialty pharma company



Endo International reached a definitive agreement to acquire Somerset Therapeutics and its affiliated contract manufacturer in India for $190 million.

Based in Somerset, N.J., Somerset Therapeutics is a specialty pharmaceutical company that develops and markets sterile injectable products. Its Bangalore, India, affiliate, Wintac Ltd., operates as Somerset Therapeutics' contract developer and manufacturer.

Paul Campanelli, president and CEO of Endo, said the acquisition will expand the product portfolio of its Par Sterile Products business Endo acquired when it\s paid $8 billion to buy Par Pharmaceutical of Woodcliff Lake, N.J., in 2015.

"Additionally," Campanelli said, "Wintac's strong sterile R&D and high-quality manufacturing capabilities have contributed greatly to Somerset Therapeutics' steady revenue growth. We see significant opportunities to leverage our existing sales and marketing capabilities as we seek to maximize the value of the current and expected future Somerset Therapeutics' products."

Somerset Therapeutics' portfolio includes eight commercial products as well as a pipeline of more than 40 others – more than 25 of which have been submitted for approval by the Food and Drug Administration.

"Par has deep experience in the growing U.S. sterile injectable drugs market," said Dr. Veerappan Subramanian, chairman and CEO of Somerset Therapeutics, in a statement. "They are well-suited to move Somerset Therapeutics and Wintac's business to the next stage of development and growth."

The deal, which requires regulatory approvals in the United States and India, is expected to close by the end of the year. After the deal is finalized, Somerset Therapeutics will become a wholly owned subsidiary of Par Pharmaceutical and the Wintac business will become part of Par Formulations Private Ltd.

K&L Gates and Shardul Amarchand Mangaldas & Co. are acting as Endo's legal counsel for the transaction.


(0)
(0)




Engineer by trade & Swing Trader at Heart!

Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW


CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment










Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us